SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending due to the approval of its merger with Strive Enterprises, paving the way for a Bitcoin treasury company. The community is excited about the potential for a short squeeze, with some drawing comparisons to other high-flying crypto plays. With potential access to significant capital post-merger, discussions are centered around the stock's potential valuation and ability to outperform Bitcoin itself.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to a surprise announcement of a warrant dividend for shareholders, sparking discussions around share lending and potential for a short squeeze. The community is analyzing the implications of these warrants, particularly how they may impact shorts and the stock's price movement. Positive earnings are adding fuel to the fire, with many expecting significant price swings.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is trending following its earnings report, despite missing estimates, due to strong forward guidance and significant growth in cloud infrastructure revenue, particularly from multi-cloud databases. The community is focused on the company's massive backlog and potential for future growth in the AI space, leading to a debate about whether the stock's surge is justified or if it's a sign of a market bubble. Discussions also revolve around the potential impact on other tech stocks and Oracle's position in the cloud computing sector.

QMMM Holdings Ltd. engages in the provision of digital advertising services. It offers interactive design, animation, art-tech and virtual technologies used in commercial campaigns. It has worked with domestic and international banks, real estate developers, amusement parks, international sports apparel, footwear brands, luxury cosmetic products, and international brands. The company was founded by Bun Kwai on July 29, 2022 and is headquartered in Hong Kong.

QMMM Holdings Ltd. - Ordinary Shares - Class A

QMMM Holdings Ltd.

QMMM is trending due to a massive short squeeze following news of a new crypto treasury strategy, leading to extreme volatility and significant gains for some traders. Community discussions revolve around the potential for continued upward momentum versus an imminent pullback, with comparisons to other high-flying stocks in the sector. Speculation abounds regarding market manipulation and the risks associated with China-based stocks.

CaliberCos, Inc. operates as an asset management firm. It provides various support services including asset management & fund set-up services, as well as lending support, construction & development management, and real estate brokerage services. The company was founded by John Christopher Loeffler II and Jennifer Schrader in January 2009 and is headquartered in Scottsdale, AZ.

CaliberCos Inc - Ordinary Shares - Class A

CaliberCos Inc 

CaliberCos ($CWD) is trending due to a volatile trading day, with discussions focusing on potential manipulation and short squeezes after a large intraday price swing. Community members are debating whether the stock will recover or if it's a pump and dump, while also comparing it to other high-flying stocks like $QMMM and $OCTO. The company's recent announcement of investing in Chainlink tokens is also a key point of discussion.

Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending amid growing investor interest in AI and e-commerce, with discussions around its potential for high growth and comparisons to other AI companies. The community is actively debating entry points, holding strategies, and the impact of upcoming earnings, while also highlighting the company's partnerships and patented technology. Some are expressing concerns about dilution and short selling, while others are very bullish for a run to double digits.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the following segments: Design Automation, Design IP, and Software Integrity. The Design Automation segment includes silicon design, verification products and services, system integration products and services, digital, custom, and FPGA IC design software, verification software and hardware products, and manufacturing software products. The Software Integrity segment includes a solution for building security and compliance testing into the customers' software development lifecycle and supply chain. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys is trending due to mixed reactions to its recent earnings report and future outlook, with investors focused on the company's exposure to macro uncertainties and the potential impact of its pending acquisition of Ansys. While some community members express confidence in the company's long-term prospects and AI-driven growth, others are concerned about the conservative guidance and its effect on the stock's valuation.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending as investors discuss its upcoming earnings report and the potential impact on the stock's valuation, with the community weighing positive analyst sentiment against concerns about profitability. A key point of discussion revolves around the company's position in the cybersecurity sector relative to competitors and potential for long-term growth. Some traders are also focused on short-term strategies, anticipating volatility around the earnings release.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Gitlab, Inc. provides code hosting and collaboration platform services. It offers continuous integration, source code management, out-of-the-box pipelines, agile development, and value stream management. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in Dover, DE.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around Cingulate spiked Tuesday after Phase 3 data confirmed that its lead candidate, CTx-1301, significantly improved ADHD symptoms in pediatric patients within five weeks of treatment.At Tuesday's close, Cingulate shares fell 4.99% to $3.62 and slipped further 1.66% to $3.56 in after-hours trading.According to the Kansas-based biotech, children who took CTx-1301 at doses of 18.75 mg, 25 mg, and 37.5 mg experienced significant reductions in their ADHD-RS-5 scores.Dr. Raul Silva, chief science officer at Cingulate, revealed the possibility of CTx-1301 becoming a primary treatment option for ADHD after demonstrating effect sizes between 0.737 and 1.185, which surpass the industry standard of 0.73 for long-duration stimulants.CEO Shane Schaffer identified the findings as a “significant value inflection point” while confirming that the company plans to file a New Drug Application (NDA) this summer.CTx-1301 uses Cingulate’s Precision Timed Release platform to provide a single daily dose, which begins working in the morning and maintains effectiveness throughout the day.After receiving FDA approval, the company plans to offer eight different dosage strengths to address the pediatric and adult ADHD markets.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,700% surge in 24-hour message volume.One user highlighted the forthcoming FDA submission as a key milestone and suggested that the recent decline in share price may offer a buying opportunity.&nbsp;<stembedurl>https://stocktwits.com/Duke1979/message/615297512</stembedurl>Another user was more cautious, noting that the effect size observed in the pediatric trial appeared lower than earlier projections. However, they acknowledged that sustained efficacy throughout the day could remain a key differentiator.<stembedurl>https://stocktwits.com/TheSterl/message/615215732</stembedurl>The stock has declined 29% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate Retail Buzz Surges As ADHD Drug Shows Phase 3 Pediatric Efficacy

Phase 3 data showed the company’s ADHD drug, CTx-1301, significantly improved symptoms in children within five weeks. The company plans to file for FDA approval this summer.

Equity

Cingulate Inc.'s shares generated heightened retail chatter on Wednesday after receiving the FDA's pre-New Drug Application (NDA) meeting minutes for its primary asset CTx-1301 that targets ADHD with a daily stimulant treatment.Cingulate shares rose 8.7% to close at $4.25 on Tuesday but slipped 4.2% to $4.07 in after-hours trading.Following a pre-NDA meeting on April 2, the company confirmed that it will submit an NDA for CTx-1301 in the summer of 2025 based on the FDA’s feedback.&nbsp;The formulation CTx-1301 contains dexmethylphenidate and employs Cingulate’s Precision Timed Release technology to provide three doses during specific times of the day.&nbsp;The technology aims to overcome the problem of reduced effectiveness in existing stimulant treatments during the afternoon hours.The FDA minutes confirmed that the existing nonclinical safety data sufficiently support the NDA submission.The agency entered into a post-approval agreement with Cingulate to gather stability data for six intermediate dose strengths, spanning from 12.5 mg to 43.75 mg.The regulatory body recognized a scientific connection to Focalin XR, which permitted Cingulate to benefit from existing data on drug effectiveness and safety.&nbsp;The agency found the company’s integrated safety and efficacy summary approaches reasonable.One user said the stock could reach $6, citing a sharp spike to $5.16 as a signal of potential upward momentum.&nbsp;On Stocktwits, retail sentiment was ‘bullish’ amid a 1,600% surge in 24-hour message volume.<stembedurl>https://stocktwits.com/doublenickels55/message/614579894</stembedurl>Another user highlighted the absence of negative news and reaffirmed confidence in the NDA timeline, noting the company remains on track for a summer submission.<stembedurl>https://stocktwits.com/fullobullz/message/614577626</stembedurl>The stock has declined 16.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug

CTx-1301 employs its Precision Timed Release system to administer three doses of dexmethylphenidate throughout the day for managing ADHD symptoms.

What's Going On With Cingulate Shares Recently?

Cingulate Inc. (NASDAQ: CING) shares are soaring Friday. the stock is trading with a session volume of 3.297 million shares, approaching its 100-day average volume of 3.654 million shares.
read more...

Cingulate Shares Are Trading By More Than 200% Friday: What You Need To Know

Cingulate Inc. (NASDAQ: CING) shares are on an upward trajectory Friday. It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301...

<a href="https://stocktwits.com/symbol/CING">Cingulate Inc</a>. (CING) shares skyrocketed over 85% in pre-market trading on Friday, becoming the top trending stock on Stocktwits. The surge comes after the stock rallied nearly 160% on Thursday, triggered by the company's announcement of a European patent for its ADHD drug candidate, CTx-1301.This patent expands Cingulate's intellectual property protection to include up to 30 European countries, adding to its existing patents in Australia, Canada, and Israel. The company is also pursuing patents in Hong Kong, South Korea, and the United States.ADHD is a significant global health issue, affecting millions worldwide. Cingulate's focus on developing treatments for ADHD aligns with its broader strategy of utilizing its proprietary PTR technology for other therapeutic areas, such as anxiety disorders.The patent news has injected a much-needed dose of optimism into the stock, which has lost over 94% of its value this year due to several headwinds.The company reported disappointing Q2 earnings and has been grappling with financial challenges, including a significant cash burn and a history of top executive departures.Cingulate has a cash balance of just $0.4 million as of June 30, 2024. To address this, the company raised $1.6 million in July through warrant inducement and plans to seek additional funding.A regulatory filing last year warned of potential bankruptcy if financial issues persisted.<stembedurl>https://stocktwits.com/SelectiveTrader/message/583139933</stembedurl>Despite these challenges, the European patent news has reignited interest in Cingulate. However, it remains to be seen if this momentum can be sustained and if the company can successfully navigate its financial hurdles to capitalize on its drug development pipeline. &nbsp;

ADHD is a significant global health issue, affecting millions worldwide. Image via Vecteezy

Cingulate Stock Is Hottest Talk Of Retail Street After Europe Patent For ADHD Drug Candidate

Retail investors, buoyed by the news, are actively discussing the stock on Stocktwits. However, some remain cautious due to the company's troubled history and ongoing financial challenges.

Top 5 Trending Stocks Of The Day: Amazon, AST Spacemobile, Cingulate, Applied Materials, And Tesla

On Thursday, major U.S. indices closed higher, with the Dow Jones Industrial Average increasing by 1.4% to 40,563.06.
read more...

What's Going On With Cingulate Shares Today?

Cingulate shares are surging, trading over 173% higher today. Here's what's driving the movement.
read more...

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

$17.8 Million Raised Since Beginning of 2023$9.1 Million of Debt Converted to Equity at a PremiumPhase 3 ADHD Data Continues to Impress KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE...

Cingulate reports Q4 EPS net loss $6.9M

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cingulate CEO talks about the pharmaceutical company's road ahead after tough 2023

CEO Shane Schaffer says a ripple from the collapse of Silicon Valley Bank set in motion a tough financial year for his Kansas City, Kansas, company...

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

CING
Cingulate Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CING News

CING Cingulate Inc